LONDON, March 24 (Reuters) - Britain's healthcare cost agency has recommended against using Bayer's new prostate cancer drug Xofigo on the state health service because the German firm did not provide evidence on how well it worked compared to other therapies.
Read more here >> Reuters | Quail eggs
Read more here >> Reuters | Quail eggs
